Insights on CT Lung Screening and Radiation Dose

M. Mahesh, MS, PhD, FAAPM, FACR, FACMP, FSCCT, FIOMP

Professor of Radiology and Cardiology
Johns Hopkins University School of Medicine
Joint Appointment - Johns Hopkins School of Public Health
Baltimore, MD, USA

@mmahesh1

Disclosures

- Travels Funds as Board Member of
  - American College of Radiology (ACR)
  - American Association of Physicists in Medicine (AAPM)
  - International Organization of Medical Physics (IOMP)
- Book Royalty from Lippincott Williams & Wilkins

@mmahesh1
Estimated Cancer Deaths in the US in 2018

- Lung and Bronchus: 154,060
- Female Breast: 41,400
- Pancreas: 44,330
- Colon and Rectum: 50,630
- Other: 319,230

https://doi.org/10.1148/radiol.2018180212
Outline

• National Lung Screening Trial (NLST)
• Low Dose CT (LDCT) protocol
• Benefits vs Harms
• Radiation Exposure Concerns
• New USPSTF recommendations
• Barriers to lung cancer screening

National Lung Screening Trial\(^1\) (NLST)

- 53,400 with half assigned for LDCT and half for chest radiograph
- 55-74 years of age, history of smoking of ~30 pack years\(^*\) and former smokers quit within 15 years
- 2002-2004 enrollment – study stopped midway in 2010 since significant reduction in rates of death with LDCT arm
- 20.0% decrease in mortality from lung cancer observed in LDCT group as compared with radiography group (3 times higher)

\(^*\)one pack-year = smoking one pack per day for one year; 1 pack = 20 cigarettes

\(^1\) Mahesh M, Site Physicist - NLST Trial Research Team  
NLST Low Dose CT (LDCT) Protocol

- Protocols developed by medical physicists* in the trial
- MDCT scanners with minimum of 4 channels included
- 1.5 mSv - average effective dose with low dose chest CT
- ~8 mSv - average effective dose for diagnostic chest CT
- Chest radiographs with screen-film or digital radiography

*Mahesh M, Site Physicist - NLST Trial Research Team


Screening for Lung Cancer with Low Dose CT

Radiology imaging facility eligibility criteria:
- Perform LDCT with CTDI\text{vol} of ≤ 3.0 mGy for standard size patients (5’ 7” & ~ 155 lbs) with appropriate modifications in CTDI\text{vol} for smaller patients for larger patients
- Smoking cessation interventions for current smokers available
- Submits data to CMS-approved registry for each LDCT lung cancer screening performed

www.CMS.gov
**LDCT: Benefits vs Harms**

**Benefits**
- 20% reduction in mortality (ACRIN-NLST trial)
- 62% of LDCT-arm screen-detected cancers were stage I
- 93.7% LDCT test sensitivity
- All-cause 5-year survival of screen-detected cancers was 55% for subjects >65 years

**Harms**
- False Positive - ~27% in NLST trial
- Overdiagnosis - ~11%
- Incidental Findings
- Radiation Dose – excess risk 0.23% for males & 0.85% for females – compared to 15% lifetime risk of future lung cancers for current smokers >55 years

*Lung Cancer Manag. 2014; 3(6): 491-498*

**LDCT Lung Cancer Screening: Radiation Exposure Concerns**

- 1.5 mSv – average effective dose for annual screening of high-risk lung cancer subjects 50-75 years of age
- 0.07% - 0.23% for Males, 0.14% - 0.85% for Females – excess risk due to LDCT radiation
- 15% lifetime risk of future lung cancer for current smokers >55 years
- 1:20 – LDCT-caused (by radiation) to LDCT-averted lung cancer deaths

When should screening stop?

Lung cancer screening stop, when person

• Turns 81 years old, or
• Has not smoked in 15 or more years, or
• Develops health problem that makes him or her unwilling or unable to have surgery if lung ca is found

www.CDC.org
Exposure to LDCT for Lung Cancer Screening: Risk-Benefit Analysis

- Median radiation exposure over 10 years:
  - 9.3 mSv for men and 13.0 mSv for women
- LAR of major cancers ranged
  - 2.6 to 8.1 major cancers per 10,000 participants
- One radiation induced cancer (theoretically) expected in every 108 lung cancers detected after 10 years of LDCT screening
- Risk of radiation induced cancer can be considered acceptable in light of substantial mortality reduction associated with LDCT screening

Benefits vs Harms of LDCT Lung Ca screening

- Due to high mortality rate from lung cancer, and the ability to easily identify a high-risk population, LDCT screening potentially has a favorable cost-effectiveness ratio (cost per quality adjusted life year gained)
Lung Cancer Screening CT

Radiation Dose Management

- CTDIvol must be ≤ 3.0 mGy for a standard sized patient, as measured using the 32-cm diameter CTDI phantom. By definition, a standard sized patient is approximately 5'7" and 155 pounds or 170 cm and 70 kg, with a BMI = 24.

<table>
<thead>
<tr>
<th>Dose Descriptor</th>
<th>Value</th>
<th>Reported at Scanner (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTDIvol*</td>
<td>≤ 3.0 mGy</td>
<td>Y</td>
</tr>
<tr>
<td>DLP*</td>
<td>≤ 75 mGy/cm</td>
<td>Y</td>
</tr>
<tr>
<td>Effective Dose (DLP x .014)**</td>
<td>≤ 1.0 mSv</td>
<td>N**</td>
</tr>
</tbody>
</table>

Approximate Volume CT Dose Index (CTDIvol) Values

- Approximate values for CTDIvol are listed for three different patient sizes:

<table>
<thead>
<tr>
<th>Patient Size</th>
<th>Approx. Weight (kg)</th>
<th>Approx. Weight (lbs)</th>
<th>Approx. CTDIvol (mGy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small Patient</td>
<td>50-70</td>
<td>110-155</td>
<td>0.25 - 2.8</td>
</tr>
<tr>
<td>Average Patient</td>
<td>70-90</td>
<td>155-200</td>
<td>0.5 - 4.3</td>
</tr>
<tr>
<td>Large Patient</td>
<td>90-120</td>
<td>200-265</td>
<td>1.0 – 5.6</td>
</tr>
</tbody>
</table>

LDCT Protocols

LUNG CANCER SCREENING CT (Selected GE scanners) with AEC (smartmA) on

<table>
<thead>
<tr>
<th>S Scout: AP</th>
<th>50-60</th>
<th>(50-60), from top of shoulder through mid-lung, if automatic exposure control is used. PA scout if manual mA is used.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen Type</td>
<td>LightSpeed 16</td>
<td>LightSpeed 16</td>
</tr>
<tr>
<td>Rotation Time (s)</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Beam Collimation (mm)</td>
<td>43756</td>
<td>20</td>
</tr>
<tr>
<td>Detector Configuration</td>
<td>16x0.625 / 16x1.25</td>
<td>16x1.25</td>
</tr>
<tr>
<td>Pitch</td>
<td>1.375</td>
<td>1.375</td>
</tr>
<tr>
<td>Speed (mm/s)</td>
<td>13.7</td>
<td>13.7</td>
</tr>
<tr>
<td>kV</td>
<td>120</td>
<td>120</td>
</tr>
<tr>
<td>mAs</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Max mA</td>
<td>130</td>
<td>130</td>
</tr>
<tr>
<td>Noise Index (smart mA)</td>
<td>34</td>
<td>29.5</td>
</tr>
<tr>
<td>FOV</td>
<td>Large Body</td>
<td>Large Body</td>
</tr>
<tr>
<td>CTDIvol</td>
<td>2.4 / 2.4 mGy</td>
<td>2.4 mGy</td>
</tr>
</tbody>
</table>

https://www.aapm.org/pubs/CTProtocols/
LDCT Protocols

LDCT Lung Cancer Screening Rate in US in 2016

Only 5% - 6% of roughly 9 million individuals in US who are eligible undergo LDCT screening annually

https://doi.org/10.1148/radiol.2018180212
New Recommendations from USPSTF

- Lung cancer 2nd most common cancer and leading cause of cancer death in US
- In 2020, ~228,820 persons diagnosed with lung cancer, and ~135,720 died
- Risk factors
  - Smoking (most)
  - Increasing age
- Generally poor prognosis, with an overall 5-year survival rate of 20.5% for lung cancer
- However, early-stage lung cancer has better prognosis and more amenable to treatment

JAMA. 2021; 325(10): 962-970

Eligible for Lung Cancer Screening with LDCT according to race and ethnicity in US

Higher percentages of all racial and ethnic groups are eligible for LCS under newly adopted LCS guidelines

Radiology, 2021; 301 (3): 712-720
Barriers to Lung Cancer Screening

Key elements for population-based lung cancer screening program

- Cost-effective way needs an organized approach:
  - Equitable recruitment
  - Identification of participants at sufficient risk
  - Nodule management protocol minimizing potential harms
  - Integration of smoking cessation

https://doi.org/10.1148/radiol.2018180212

Eur Respir Rev 2021; 30: 200288
10 Pillars of Lung Cancer Screening

- Eligibility
- Education
- Exam Ordering
- Imaging Acquisition
- Imaging Review
- Communication
- Referral Network
- Quality Improvement
- Reimbursement
- Research/Frontier

RadioGraphics 2023; 44(3):e230057

ACR: Pink & Pearl Campaign
Mammography Saves Lives and So Does Lung Screening

Risk Factors for Breast and Lung Cancer

- Getting Older.
- Family history of breast or ovarian cancer.
- Early periods, before age 12.
- Drinking alcohol.
- Starting menopause after age 55.
- Having first pregnancy after age 30.
- Smoking or using tobacco products.
- Not being physically active.
- Family history of lung cancer.
- Radon exposure.
- Smoking and secondhand smoke exposure.
- Exposure to other workplace hazards, such as asbestos, arsenic, diesel exhaust, and forms of silica and chromium.

https://www.acr.org/Clinical-Resources/Lung-Cancer-Screening-Resources
Conclusions

• ~20% - Reduction in lung cancer mortality shown with LDCT
• ~1:20 – LDCT-caused (radiation) to LDCT-averted lung cancer deaths) – benefit outweighs radiation risk from screening
• ~6% - In spite, uptake of LDCT screening is still low
• Effective lung cancer screening programs are needed for equitable outreach and higher uptakes
Barriers to Lung Cancer Screening Engagement

• Patient encountered barriers
  • Unawareness of screening programs (language barriers, lack of clinician)
  • Perceptual barriers (fear of lung cancer diagnosis and perceived stigma)
  • Cost concerns (underinsured, costs of further workup, loss of income)
  • Challenges in accessing screening sites (homelessness, lack of transportation, geographic access to medical centers)

• Providers encountered barriers
  • Unfamiliarity with eligibility criteria and insurance coverage
  • Challenges identifying eligible patients
  • Insufficient time and/or knowledge of how to conduct shared decision-making
  • Need for guidance with management of lung cancer screening findings
  • Skepticism about benefits of screening

• More research required to identify effective strategies to reach and engage target population and to ensure higher uptake in high-quality lung cancer screening programs

Radiology 2019; 290:278–287